Corvus Pharmaceuticals, Inc. (CRVS) Misses Q3 EPS by 49c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q3 EPS of ($0.60), $0.49 worse than the analyst estimate of ($0.11).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Micron Technology (MU) PT Raised to $1,300 at Bernstein SocGen Group
• MDA Space Ltd (MDA:CN) (MDA) PT Raised to Cdn$68 at BMO Capital
• JPMorgan Upgrades YDUQS Participacoes SA (YDUQ3:BZ) to Overweight